William Blair Starts Portola Pharmaceuticals (PTLA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Morgan Stanley Starts Portola Pharmaceuticals (PTLA) at Overweight
June 17, 2013 7:26 AM EDTMorgan Stanley initiates coverage on Portola Pharmaceuticals (NASDAQ: PTLA) with a Overweight. PT $32.00.
For an analyst ratings summary and ratings history on Portola Pharmaceuticals click here. For more ratings news on Portola Pharmaceuticals click here.
Shares of Portola Pharmaceuticals closed at $20.05 yesterday, with a 52 week range of $14.75-$29.79.... More
